Skip to content

Study · Not a test of the peptide alone · 2021

9 results

Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.

McCrimmon RJ, Falla E, Sha JZ, Alsaleh AJO, Lew E, Hudson R, Baxter M, Palmer K

Diabetes therapy : research, treatment and education of diabetes and related disorders29 Oct 2021Cited by 9 (Europe PMC)

PMID34714523 (opens in a new tab)PMCIDPMC8586275 (opens in a new tab)DOI10.1007/s13300-021-01159-y (opens in a new tab)PepBankPUB-34714523
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a UK diabetes model, insulin glargine plus dulaglutide cost more than iGlarLixi over a lifetime.

    In plain wordsA computer model predicted higher lifetime costs for insulin glargine plus dulaglutide than for iGlarLixi.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePredicted lifetime costs
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, iDegLira cost more than iGlarLixi over a lifetime.

    In plain wordsA computer model predicted higher lifetime costs for iDegLira than for iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    IncreasePredicted lifetime costs with iDegLira
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, basal insulin plus liraglutide cost more than iGlarLixi over a lifetime.

    In plain wordsA computer model predicted higher lifetime costs for basal insulin plus liraglutide than for iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    IncreasePredicted lifetime costs with basal insulin plus liraglutide
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a UK diabetes model, insulin glargine plus dulaglutide yielded comparable QALYs to iGlarLixi.

    In plain wordsA computer model predicted comparable quality-adjusted survival with insulin glargine plus dulaglutide and iGlarLixi.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePredicted QALYs
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 05Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, iDegLira and iGlarLixi yielded identical QALYs.

    In plain wordsA computer model predicted identical quality-adjusted survival with iDegLira and iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredicted QALYs with iDegLira
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, basal insulin plus liraglutide yielded comparable QALYs to iGlarLixi.

    In plain wordsA computer model predicted comparable quality-adjusted survival with basal insulin plus liraglutide and iGlarLixi.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredicted QALYs with basal insulin plus liraglutide
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a UK diabetes model, iGlarLixi had positive net monetary benefit versus insulin glargine plus dulaglutide.

    In plain wordsA computer model favored iGlarLixi over insulin glargine plus dulaglutide for net monetary benefit.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseRelative net monetary benefit
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  8. 08Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, iGlarLixi had positive net monetary benefit versus iDegLira.

    In plain wordsA computer model favored iGlarLixi over iDegLira for net monetary benefit.

    Peptide
    Liraglutide
    Outcome
    DecreaseRelative net monetary benefit with iDegLira
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 09Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a UK diabetes model, iGlarLixi had positive net monetary benefit versus basal insulin plus liraglutide.

    In plain wordsA computer model favored iGlarLixi over basal insulin plus liraglutide for net monetary benefit.

    Peptide
    Liraglutide
    Outcome
    DecreaseRelative net monetary benefit with basal insulin plus liraglutide
    Study

    n: not reported in source

    IQVIA Core Diabetes Model
    Comparator
    iGlarLixi
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira).
    2 context sentences
    Summary · context
    A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula)…
    Summary · context
    The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    22 Oct 2026, 02:25 UTC

    Study results updated

  3. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.